-
1
-
-
0027769876
-
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
-
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
-
(1993)
Nature
, vol.366
, pp. 704-707
-
-
Serrano, M.1
Hannon, G.J.2
Beach, D.3
-
2
-
-
0028121279
-
A cell cycle regulator potentially involved in genesis of many tumor types
-
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types [see comments]. Science 1994;264:436-40.
-
(1994)
Science
, vol.264
, pp. 436-440
-
-
Kamb, A.1
Gruis, N.A.2
Weaver-Feldhaus, J.3
Liu, Q.4
Harshman, K.5
Tavtigian, S.V.6
Stockert, E.7
Day R.S. III8
Johnson, B.E.9
Skolnick, M.H.10
-
3
-
-
0029587551
-
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
-
Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
-
(1995)
Cell
, vol.83
, pp. 993-1000
-
-
Quelle, D.E.1
Zindy, F.2
Ashmun, R.A.3
Sherr, C.J.4
-
5
-
-
0032549704
-
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
-
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
-
(1998)
Cell
, vol.92
, pp. 713-723
-
-
Pomerantz, J.1
Schreiber-Agus, N.2
Liegeois, N.J.3
Silverman, A.4
Alland, L.5
Chin, L.6
Potes, J.7
Chen, K.8
Orlow, I.9
Lee, H.W.10
Cordon-Cardo, C.11
DePinho, R.A.12
-
6
-
-
0029091503
-
Frequency of homozygous deletion at p16/CDKN2 in primary human tumors
-
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 1995; 11:210-2.
-
(1995)
Nat Genet
, vol.11
, pp. 210-212
-
-
Cairns, P.1
Polascik, T.J.2
Eby, Y.3
Tokino, K.4
Califano, J.5
Merlo, A.6
Mao, L.7
Herath, J.8
Jenkins, R.9
Westra, W.10
-
7
-
-
0031717333
-
Molecular alterations in bladder cancer
-
Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-33.
-
(1998)
Urol Res
, vol.26
, pp. 223-233
-
-
Orntoft, T.F.1
Wolf, H.2
-
8
-
-
0032484559
-
Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder
-
Van Tilborg AA, Hekman AC, Vissers KJ, van der Kwast TH, Zwarthoff EC. Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder. Int J Cancer 1998;75:9-14.
-
(1998)
Int J Cancer
, vol.75
, pp. 9-14
-
-
Van Tilborg, A.A.1
Hekman, A.C.2
Vissers, K.J.3
Van der Kwast, T.H.4
Zwarthoff, E.C.5
-
9
-
-
0028853608
-
Deletion of the p16 and p15 genes in human bladder tumors
-
Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87: 1524-9.
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 1524-1529
-
-
Orlow, I.1
Lacombe, L.2
Hannon, G.J.3
Serrano, M.4
Pellicer, I.5
Dalbagni, G.6
Reuter, V.E.7
Zhang, Z.F.8
Beach, D.9
Cordon-Cardo, C.10
-
10
-
-
0343923480
-
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS 1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization
-
Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS 1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997;19:84-9.
-
(1997)
Genes Chromosomes Cancer
, vol.19
, pp. 84-89
-
-
Balazs, M.1
Carroll, P.2
Kerschmann, R.3
Sauter, G.4
Waldman, F.M.5
-
11
-
-
0029146575
-
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer
-
Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995;4:1569-77.
-
(1995)
Hum Mol Genet
, vol.4
, pp. 1569-1577
-
-
Williamson, M.P.1
Elder, P.A.2
Shaw, M.E.3
Devlin, J.4
Knowles, M.A.5
-
12
-
-
0028875205
-
Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
-
Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55: 4531-5.
-
(1995)
Cancer Res
, vol.55
, pp. 4531-4535
-
-
Gonzalez-Zulueta, M.1
Bender, C.M.2
Yang, A.S.3
Nguyen, T.4
Beart, R.W.5
Van Tornout, J.M.6
Jones, P.A.7
-
13
-
-
0028033422
-
Rates of p16 (MTS1) mutations in primary tumors with 9p loss
-
Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-7.
-
(1994)
Science
, vol.265
, pp. 415-417
-
-
Cairns, P.1
Mao, L.2
Merlo, A.3
Lee, D.J.4
Schwab, D.5
Eby, Y.6
Tokino, K.7
Van der Riet, P.8
Blaugrund, J.E.9
Sidransky, D.10
-
14
-
-
0029005856
-
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression
-
Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995;146: 1199-206.
-
(1995)
Am J Pathol
, vol.146
, pp. 1199-1206
-
-
Gruis, N.A.1
Weaver-Feldhaus, J.2
Liu, Q.3
Frye, C.4
Eeles, R.5
Orlow, I.6
Lacombe, L.7
Ponce-Castaneda, V.8
Lianes, P.9
Latres, E.10
-
15
-
-
0028070985
-
p16 gene in uncultured tumors
-
Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA. p16 gene in uncultured tumors [letter] [see comments]. Nature 1994;370:183-4.
-
(1994)
Nature
, vol.370
, pp. 183-184
-
-
Spruck C.H. III1
Gonzalez-Zulueta, M.2
Shibata, A.3
Simoneau, A.R.4
Lin, M.F.5
Gonzales, F.6
Tsai, Y.C.7
Jones, P.A.8
-
16
-
-
0028949211
-
Infrequent somatic mutation of the MTSI gene in primary bladder carcinomas
-
Kai M, Arakawa H, Sugimoto Y, Murata Y, Ogawa M, Nakamura Y. Infrequent somatic mutation of the MTSI gene in primary bladder carcinomas. Jpn J Cancer Res 1995;86:249-51.
-
(1995)
Jpn J Cancer Res
, vol.86
, pp. 249-251
-
-
Kai, M.1
Arakawa, H.2
Sugimoto, Y.3
Murata, Y.4
Ogawa, M.5
Nakamura, Y.6
-
17
-
-
0028789685
-
Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers
-
Miyamoto H, Kubota Y, Fujinami K, Dobashi Y, Kondo K, Yao M, Shuin T, Hosaka M. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. Oncol Res 1995;7:327-30.
-
(1995)
Oncol Res
, vol.7
, pp. 327-330
-
-
Miyamoto, H.1
Kubota, Y.2
Fujinami, K.3
Dobashi, Y.4
Kondo, K.5
Yao, M.6
Shuin, T.7
Hosaka, M.8
-
18
-
-
0028879681
-
Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors
-
Packenham JP, Taylor JA, Anna CH, White CM, Devereux TR. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinog 1995;14:147-51.
-
(1995)
Mol Carcinog
, vol.14
, pp. 147-151
-
-
Packenham, J.P.1
Taylor, J.A.2
Anna, C.H.3
White, C.M.4
Devereux, T.R.5
-
19
-
-
0031067521
-
Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas
-
Asamoto M, Iwahori Y, Okamura T, Shirai T, Tsuda H. Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas. Jpn J Clin Oncol 1997;27:22-5.
-
(1997)
Jpn J Clin Oncol
, vol.27
, pp. 22-25
-
-
Asamoto, M.1
Iwahori, Y.2
Okamura, T.3
Shirai, T.4
Tsuda, H.5
-
20
-
-
0033087687
-
p16 involvement in primary bladder tumors: Analysis of deletions and mutations
-
Baud E, Catilina P, Bignon YJ. p16 involvement in primary bladder tumors: analysis of deletions and mutations. Int J Oncol 1999;14: 441-5.
-
(1999)
Int J Oncol
, vol.14
, pp. 441-445
-
-
Baud, E.1
Catilina, P.2
Bignon, Y.J.3
-
21
-
-
0028018501
-
MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p
-
Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 1994;3:1841-5.
-
(1994)
Hum Mol Genet
, vol.3
, pp. 1841-1845
-
-
Ueki, K.1
Rubio, M.P.2
Ramesh, V.3
Correa, K.M.4
Rutter, J.L.5
Von Deimling, A.6
Buckler, A.J.7
Gusella, J.F.8
Louis, D.N.9
-
22
-
-
0032517341
-
The p161NK4a/CDKN2A tumor suppressor and its relatives
-
Ruas M, Peters G. The p161NK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
-
(1998)
Biochim Biophys Acta
, vol.1378
-
-
Ruas, M.1
Peters, G.2
-
23
-
-
0032545582
-
Mutations in the CDKN2A (p161NK4a) gene in microdissected sporadic primary melanomas
-
Kumar R, Lundh Rozell B, Louhelainen J, Hemminki K. Mutations in the CDKN2A (p161NK4a) gene in microdissected sporadic primary melanomas. Int J Cancer 1998;75:193-8.
-
(1998)
Int J Cancer
, vol.75
, pp. 193-198
-
-
Kumar, R.1
Lundh Rozell, B.2
Louhelainen, J.3
Hemminki, K.4
-
24
-
-
0035923248
-
A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare
-
Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K. A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 2001;95:388-93.
-
(2001)
Int J Cancer
, vol.95
, pp. 388-393
-
-
Kumar, R.1
Smeds, J.2
Berggren, P.3
Straume, O.4
Rozell, B.L.5
Akslen, L.A.6
Hemminki, K.7
-
25
-
-
0033518889
-
CDKN2A variants in a population-based sample of Queensland families with melanoma
-
Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 446-452
-
-
Aitken, J.1
Welch, J.2
Duffy, D.3
Milligan, A.4
Green, A.5
Martin, N.6
Hayward, N.7
-
26
-
-
0036313607
-
Significant impact of promoter hypermethylation and the C→T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase
-
Straume O, Smeds J, Kumar R, Hemmiki K, Akslen LA. Significant impact of promoter hypermethylation and the C→T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002;161:229-37.
-
(2002)
Am J Pathol
, vol.161
, pp. 229-237
-
-
Straume, O.1
Smeds, J.2
Kumar, R.3
Hemmiki, K.4
Akslen, L.A.5
-
27
-
-
0033932154
-
Analysis of G(1)/S checkpoint regulators in metastatic melanoma
-
Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, Hahka-Kemppinen M, Punnonen K, Jansen CT, Hemminki K, Pyrhonen S. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000;28:404-14.
-
(2000)
Genes Chromosomes Cancer
, vol.28
, pp. 404-414
-
-
Sauroja, I.1
Smeds, J.2
Vlaykova, T.3
Kumar, R.4
Talve, L.5
Hahka-Kemppinen, M.6
Punnonen, K.7
Jansen, C.T.8
Hemminki, K.9
Pyrhonen, S.10
-
29
-
-
0033965916
-
Bladder cancer: Allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade
-
Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijkstrom H. Norming U, Borgstrom E, Hansson J, Sandstedt B, Steineck G. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res 2000;6:610-5.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 610-615
-
-
Wada, T.1
Louhelainen, J.2
Hemminki, K.3
Adolfsson, J.4
Wijkstrom, H.5
Norming, U.6
Borgstrom, E.7
Hansson, J.8
Sandstedt, B.9
Steineck, G.10
-
32
-
-
0025185642
-
Staging of bladder cancer: Is the tumor, node, metastasis system adequate?
-
Hall RR, Prout GR. Staging of bladder cancer: is the tumor, node, metastasis system adequate? Semin Oncol 1990;17:517-23.
-
(1990)
Semin Oncol
, vol.17
, pp. 517-523
-
-
Hall, R.R.1
Prout, G.R.2
-
33
-
-
0013808343
-
Classification of bladder tumors based on the cellular pattern. Preliminary report of a clinicalpathological study of 300 cases with a minimum follow-up of eight years
-
Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumors based on the cellular pattern. Preliminary report of a clinicalpathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965;130:371-8.
-
(1965)
Acta Chir Scand
, vol.130
, pp. 371-378
-
-
Bergkvist, A.1
Ljungqvist, A.2
Moberger, G.3
-
34
-
-
0032794625
-
Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): Homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas
-
Kumar R, Smeds J, Lundh Rozell B, Hemminki K. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 1999;9:138-47.
-
(1999)
Melanoma Res
, vol.9
, pp. 138-147
-
-
Kumar, R.1
Smeds, J.2
Lundh Rozell, B.3
Hemminki, K.4
-
35
-
-
0034672289
-
Single nucleotide polymorphism analyses of the human proliferating cell nuclear antigen (pCNA) and flap endonuclease (FEN1) genes
-
Ma X, Jin Q, Forsti A, Hemminki K, Kumar R. Single nucleotide polymorphism analyses of the human proliferating cell nuclear antigen (pCNA) and flap endonuclease (FEN1) genes. Int J Cancer 2000;88:938-42.
-
(2000)
Int J Cancer
, vol.88
, pp. 938-942
-
-
Ma, X.1
Jin, Q.2
Forsti, A.3
Hemminki, K.4
Kumar, R.5
-
36
-
-
9444276546
-
Prevalence of germ-line mutations in p16, p19ARF and CDK4 in familial melanoma: Analysis of a clinic-based population
-
FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. Prevalence of germ-line mutations in p16, p19ARF and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996;93:8541-5.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 8541-8545
-
-
FitzGerald, M.G.1
Harkin, D.P.2
Silva-Arrieta, S.3
MacDonald, D.J.4
Lucchina, L.C.5
Unsal, H.6
O'Neill, E.7
Koh, J.8
Finkelstein, D.M.9
Isselbacher, K.J.10
Sober, A.J.11
Haber, D.A.12
-
37
-
-
0028036255
-
Two molecular pathways to transitional cell carcinoma of the bladder
-
Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
-
(1994)
Cancer Res
, vol.54
, pp. 784-788
-
-
Spruck C.H. III1
Ohneseit, P.F.2
Gonzalez-Zulueta, M.3
Esrig, D.4
Miyao, N.5
Tsai, Y.C.6
Lerner, S.P.7
Schmutte, C.8
Yang, A.S.9
Cote, R.10
-
38
-
-
0035079268
-
Molecular and kinetic features of transitional cell carcinomas of the bladder: Biological and clinical implications
-
Baithun SI, Naase M, Blanes A, Diaz-Cano SJ. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch 2001;438:289-97.
-
(2001)
Virchows Arch
, vol.438
, pp. 289-297
-
-
Baithun, S.I.1
Naase, M.2
Blanes, A.3
Diaz-Cano, S.J.4
-
39
-
-
0029042453
-
The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years
-
discussion 1826-7
-
Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-6; discussion 1826-7.
-
(1995)
J Urol
, vol.153
, pp. 1823-1826
-
-
Holmang, S.1
Hedelin, H.2
Anderstrom, C.3
Johansson, S.L.4
-
40
-
-
0034101197
-
The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology?
-
Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000;6:637-41.
-
(2000)
Nat Med
, vol.6
, pp. 637-641
-
-
Conne, B.1
Stutz, A.2
Vassalli, J.D.3
-
41
-
-
0035893756
-
Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features
-
Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-63.
-
(2001)
Cancer Res
, vol.61
, pp. 8659-8663
-
-
Maruyama, R.1
Toyooka, S.2
Toyooka, K.O.3
Harada, K.4
Virmani, A.K.5
Zochbauer-Muller, S.6
Farinas, A.J.7
Vakar-Lopez, F.8
Minna, J.D.9
Sagalowsky, A.10
Czerniak, B.11
Gazdar, A.F.12
-
42
-
-
0033787302
-
DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder
-
Florl AR, Franke KH, Niederacher D, Gerharz CD, Seifert HH, Schulz WA. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder [In Process Citation]. Lab Invest 2000;80:1513-22.
-
(2000)
Lab Invest
, vol.80
, pp. 1513-1522
-
-
Florl, A.R.1
Franke, K.H.2
Niederacher, D.3
Gerharz, C.D.4
Seifert, H.H.5
Schulz, W.A.6
-
43
-
-
0036554966
-
p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients
-
Dominguez G, Carballido J, Silva J, Silva JM, Garcia JM, Menendez J, Provencio M, Espana P, Bonilla F. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8:980-5.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 980-985
-
-
Dominguez, G.1
Carballido, J.2
Silva, J.3
Silva, J.M.4
Garcia, J.M.5
Menendez, J.6
Provencio, M.7
Espana, P.8
Bonilla, F.9
-
44
-
-
0013147064
-
Detecting homozygous deletions in the CDKN2A/ARF gene in urinary bladder cancer using real-time PCR
-
in press
-
Berggren P, Kumar R, Sakano S, Hemminki L, Wada T, Steineck G, Adolfsson J, Larsson P, Norming U, Wijkstrom H, Hemmiki K. Detecting homozygous deletions in the CDKN2A/ARF gene in urinary bladder cancer using real-time PCR. Clin Cancer Res 2002 (in press).
-
(2002)
Clin Cancer Res
-
-
Berggren, P.1
Kumar, R.2
Sakano, S.3
Hemminki, L.4
Wada, T.5
Steineck, G.6
Adolfsson, J.7
Larsson, P.8
Norming, U.9
Wijkstrom, H.10
Hemmiki, K.11
|